OncoMatch/Clinical Trials/NCT06087614
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Is NCT06087614 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cisplatin for head and neck squamous cell carcinoma.
Treatment: Cisplatin — DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Excluded: CDKN2A p16 positive
HPV (p16) positive tumours [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: surgery
Prior surgery and/or radiation therapy given for any HNC
Cannot have received: radiation therapy
Prior surgery and/or radiation therapy given for any HNC
Lab requirements
Blood counts
Hb: > 10g/dl (corrected); TLC: > 4,000 per cumm; Platelet: >1.5Lakh per cumm
Kidney function
Kidney functions within normal limits
Liver function
Liver functions within normal limits
Sufficient bone marrow reserve within the last 14 days. Hb: > 10g/dl (corrected); TLC: > 4,000 per cumm; Platelet: >1.5Lakh per cumm; Liver functions and kidney functions within normal limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06087614 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with CDKN2A alterations eligible?
No. CDKN2A p16 positive is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages